XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2024
Notes Tables |
Schedule of the Consolidated Changes in Equity | ​ Consolidated Changes in Equity (amounts in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Total
Balances at June 30, 2024 |  | 158,216 | ​ | $ | 1,582 | ​ | $ | 820,337 | ​ | $ | 1,325,247 | ​ | $ | (78,316) | ​ | $ | 2,068,850
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 33,600 | ​ |  | ​ | ​ |  | 33,600
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 18,229 | ​ |  | 18,229
Common stock issued for exercise of options |  | 577 | ​ |  | 6 | ​ |  | 23,224 | ​ |  | (2,338) | ​ |  | ​ | ​ |  | 20,892
Common stock issued for restricted stock awards |  | 50 | ​ | ​ | 1 | ​ |  | 1 | ​ |  | (2,646) | ​ |  | ​ | ​ |  | (2,644)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,688) | ​ |  | ​ | ​ |  | (12,688)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 10,146 | ​ |  | ​ | ​ |  | ​ | ​ |  | 10,146
Common stock issued to employee stock purchase plan |  | 35 | ​ | ​ | 0 | ​ |  | 2,227 | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,227
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 38 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 38
Balances at September 30, 2024 |  | 158,878 | ​ | $ | 1,589 | ​ | $ | 855,973 | ​ | $ | 1,341,175 | ​ | $ | (60,087) | ​ | $ | 2,138,650
Net earnings |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 34,890 | ​ | ​ | ​ | ​ |  | 34,890
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (25,563) | ​ | ​ | (25,563)
Share repurchases |  | (1,118) | ​ | ​ | (11) | ​ | ​ | ​ | ​ | ​ | (75,617) | ​ | ​ | ​ | ​ |  | (75,628)
Common stock issued for exercise of options |  | 132 | ​ | ​ | 1 | ​ | ​ | 5,183 | ​ | ​ | (20) | ​ | ​ | ​ | ​ |  | 5,164
Common stock issued for restricted stock awards |  | 24 | ​ | ​ | 0 | ​ | ​ | 0 | ​ | ​ | (993) | ​ | ​ | ​ | ​ |  | (993)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,736) | ​ | ​ | ​ | ​ |  | (12,736)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ | ​ | 14,335 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 14,335
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 373 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 373
Balances at December 31, 2024 |  | 157,916 | ​ | $ | 1,579 | ​ | $ | 875,864 | ​ | $ | 1,286,699 | ​ | $ | (85,650) | ​ | $ | 2,078,492
​ ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Total
Balances at June 30, 2023 |  | 157,642 | ​ | $ | 1,576 | ​ | $ | 721,543 | ​ | $ | 1,309,461 | ​ | $ | (66,064) | ​ | $ | 1,966,516
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 50,993 | ​ |  | ​ | ​ |  | 50,993
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | (11,952) | ​ |  | (11,952)
Common stock issued for exercise of options |  | 633 | ​ |  | 6 | ​ |  | 12,877 | ​ |  | (15,460) | ​ |  | ​ | ​ |  | (2,577)
Common stock issued for restricted stock awards |  | 47 | ​ | ​ | 1 | ​ |  | 0 | ​ |  | (4,768) | ​ |  | ​ | ​ |  | (4,767)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,654) | ​ |  | ​ | ​ |  | (12,654)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 9,981 | ​ |  | ​ | ​ |  | ​ | ​ |  | 9,981
Common stock issued to employee stock purchase plan |  | 33 | ​ | ​ | 1 | ​ |  | 2,093 | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,094
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112
Balances at September 30, 2023 |  | 158,355 | ​ | $ | 1,584 | ​ | $ | 746,606 | ​ | $ | 1,327,572 | ​ | $ | (78,016) | ​ | $ | 1,997,746
Net earnings |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 27,465 | ​ | ​ | ​ | ​ |  | 27,465
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 14,355 | ​ | ​ | 14,355
Share repurchases |  | (1,397) | ​ | ​ | (14) | ​ | ​ | ​ | ​ | ​ | (80,028) | ​ | ​ | ​ | ​ |  | (80,042)
Common stock issued for exercise of options |  | 157 | ​ | ​ | 1 | ​ | ​ | 4,914 | ​ | ​ | (1,074) | ​ | ​ | ​ | ​ |  | 3,841
Common stock issued for restricted stock awards |  | 27 | ​ | ​ | 0 | ​ | ​ | 0 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 0
Cash dividends |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,559) | ​ | ​ | ​ | ​ |  | (12,559)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ | ​ | 12,413 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 12,413
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 340 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 340
Balances at December 31, 2023 |  | 157,142 | ​ | $ | 1,571 | ​ | $ | 764,273 | ​ | $ | 1,261,376 | ​ | $ | (63,661) | ​ | $ | 1,963,559
Schedule of changes in Accumulated Other Comprehensive Income (Loss) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Three months ended December 31, 2024 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of September 30, 2024, net of tax | ​ | $ | 5,075 | ​ | $ | (65,162) | ​ | $ | (60,087)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (1,689) | ​ | ​ | (26,021) | ​ | ​ | (27,710)
Amounts reclassified out | ​ | ​ | 2,155 | ​ | ​ | 660 | ​ | ​ | 2,815
Total other comprehensive income (loss), before tax | ​ | ​ | 466 | ​ | ​ | (25,361) | ​ | ​ | (24,895)
Tax (expense)/benefit | ​ | ​ | (511) | ​ | ​ | (157) | ​ | ​ | (668)
Total other comprehensive income (loss), net of tax | ​ |  | (45) | ​ | ​ | (25,518) | ​ | ​ | (25,563)
Balance as of December 31, 2024, net of tax | ​ | $ | 5,030 | ​ | $ | (90,680) | ​ | $ | (85,650)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Three months ended December 31, 2023 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of September 30, 2023 net of tax: | ​ | $ | 12,512 | ​ | $ | (90,528) | ​ | $ | (78,016)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (5,669) | ​ | ​ | 17,387 | ​ | ​ | 11,718
Amounts reclassified out | ​ | ​ | 2,620 | ​ | ​ | 837 | ​ | ​ | 3,457
Total other comprehensive income (loss), before tax | ​ | ​ | (3,049) | ​ | ​ | 18,224 | ​ | ​ | 15,175
Tax (expense)/benefit | ​ | ​ | (621) | ​ | ​ | (199) | ​ | ​ | (820)
Total other comprehensive income (loss), net of tax | ​ |  | (3,670) | ​ | ​ | 18,025 | ​ | ​ | 14,355
Balance as of December 31, 2023, net of tax | ​ | $ | 8,842 | ​ | $ | (72,503) | ​ | $ | (63,661)
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Six months ended December 31, 2024 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2024, net of tax: | ​ | $ | 8,102 | ​ | $ | (86,418) | ​ | $ | (78,316)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (6,699) | ​ | ​ | (5,362) | ​ | ​ | (12,061)
Amounts reclassified out | ​ | ​ | 4,754 | ​ | ​ | 1,442 | ​ | ​ | 6,196
Total other comprehensive income (loss), before tax | ​ | ​ | (1,945) | ​ | ​ | (3,920) | ​ | ​ | (5,865)
Tax (expense)/benefit | ​ | ​ | (1,127) | ​ | ​ | (342) | ​ | ​ | (1,469)
Total other comprehensive income (loss), net of tax | ​ |  | (3,072) | ​ | ​ | (4,262) | ​ | ​ | (7,334)
Balance as of December 31, 2024, net of tax(1) | ​ | $ | 5,030 | ​ | $ | (90,680) | ​ | $ | (85,650)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Six months ended December 31, 2023 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2023, net of tax: | ​ | $ | 12,862 | ​ | $ | (78,926) | ​ | $ | (66,064)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (7,956) | ​ | ​ | 5,252 | ​ | ​ | (2,704)
Amounts reclassified out | ​ | ​ | 5,159 | ​ | ​ | 1,535 | ​ | ​ | 6,694
Total other comprehensive income (loss), before tax | ​ | ​ | (2,797) | ​ | ​ | 6,787 | ​ | ​ | 3,990
Tax (expense)/benefit | ​ | ​ | (1,223) | ​ | ​ | (364) | ​ | ​ | (1,587)
Total other comprehensive income (loss), net of tax | ​ |  | (4,020) | ​ | ​ | 6,423 | ​ | ​ | 2,403
Balance as of December 31, 2023, net of tax(1) | ​ | $ | 8,842 | ​ | $ | (72,503) | ​ | $ | (63,661)
​ (1) The Company had a net deferred tax liability for its cash flow hedge of $1.6 million and $2.7 million as of December 31, 2024 and 2023, respectively.

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration